Hollow-Fiber Bioreactors Market Report 2025

The hollow-fiber bioreactors market size has grown strongly in recent years. It will grow from $1.37 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth observed during the historic period can be attributed to the increasing production of monoclonal antibodies, the rising demand for vaccine manufacturing, growing research funding for cell culture, enhancements in ultrafiltration membrane performance, and the expansion of single-use bioprocessing platforms.

The hollow-fiber bioreactors market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth during the forecast period can be attributed to the increasing approvals of cell-based therapies, the expansion of the regenerative medicine market, the rising prevalence of chronic and degenerative diseases, the shift toward continuous manufacturing processes, and the growing demand for personalized medicine. Key trends in the forecast period include the development of nano-structured polymer composite membranes, the integration of real-time sensors and automation technologies, the adoption of artificial intelligence for process optimization, advancements in surface functionalization techniques, and ongoing research into biodegradable hollow-fiber materials.

The rising demand for cell-based therapy production is expected to drive growth in the hollow-fiber bioreactors market in the coming years. Cell-based therapy production involves manufacturing therapeutic products derived from living cells to treat diseases such as cancers, autoimmune disorders, and genetic conditions. The market demand is growing due to the need for scalable, high-yield, and consistent manufacturing platforms that maintain product quality even at high cell densities. Hollow-fiber bioreactors facilitate this process by providing a closed system with high surface area, enabling efficient expansion and harvesting of therapeutic cells under tightly controlled conditions. For example, in December 2024, the International Federation of Pharmaceutical Manufacturers and Associations reported that six first-in-class cell and gene therapies were introduced in 2023, a 50% increase from three in 2022, underscoring the growing need for efficient production platforms.

The increasing prevalence of personalized medicine is another key driver for the hollow-fiber bioreactors market. Personalized medicine customizes treatment based on a patient’s unique genetic profile, biology, and health needs. The rise of personalized medicine is fueled by advanced diagnostic technologies that allow precise identification of patient-specific disease mechanisms, improving treatment outcomes and minimizing trial-and-error approaches. Hollow-fiber bioreactors support this trend by enabling high-quality, scalable cell culture production for patient-specific therapies. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, highlighting the growing demand for flexible and efficient cell production systems.

Companies in the hollow-fiber bioreactors market are focusing on automation and scalable innovations to enhance cell culture efficiency. Advanced systems, such as automated dual-compartment bioreactors, allow independent control of cells within hollow fibers and their surrounding nutrient environment, optimizing growth and bioprocess efficiency. For example, in September 2022, Terumo Blood and Cell Technologies launched the Quantum Flex Cell Expansion System, which uses a continuous perfusion-based, hollow-fiber semipermeable membrane to create a closed, automated cell culture environment. The system offers two bioreactor sizes for scalability and flexibility, integrates Cell Processing Application software for fleet management and GMP compliance, and supports autologous and allogeneic applications, as well as viral vector and exosome production. This innovation reduces manual intervention, streamlines scalability, and accelerates the development of advanced cell therapies.

Major players in the hollow-fiber bioreactors market are General Electric Company, Veolia Environnement S.A., Thermo Fisher Scientific Inc., Mitsubishi Chemical Corporation, Kubota Corporation, DuPont de Nemours Inc., MANN+HUMMEL GmbH, Alfa Laval AB, Sartorius AG, Repligen Corporation, Shenzhen Dreamemway Environmental Products Co. Ltd., FiberCell Systems Inc., Reynolds Culligan Water, Shanghai MegaVision Membrane Engineering & Technology Co. Ltd., Memfill Tech Private Limited, FibraCast Inc., iMemFlo Membrane Technology Co. Ltd., Guangdong Skyview Environmental Science and Technology Co. Ltd., PHILOS Co. Ltd., and Blufox Engineering Pvt. Ltd.

North America was the largest region in the hollow-fiber bioreactors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hollow-fiber bioreactors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hollow-fiber bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Hollow-fiber bioreactors are sophisticated cell culture systems that utilize bundles of semi-permeable hollow fibers to provide a high surface area environment for cell growth and product synthesis. These bioreactors facilitate efficient nutrient, gas, and waste exchange, closely replicating physiological conditions. They are widely employed for high-density cell culture, protein production, and continuous perfusion processes in both biomanufacturing and research settings.

The primary product categories of hollow-fiber bioreactors include single-use and reusable systems. Single-use hollow-fiber bioreactors are designed for one-time applications, featuring pre-sterilized components that minimize the need for extensive cleaning and preparation between production cycles. They find application in cell culture, tissue engineering, biopharmaceutical production, wastewater treatment, and more, and are utilized by various end-users such as pharmaceutical and biotechnology companies, research institutions, and contract research organizations.

The hollow-fiber bioreactors market research report is one of a series of new reports that provides hollow-fiber bioreactors market statistics, including hollow-fiber bioreactors industry global market size, regional shares, competitors with a hollow-fiber bioreactors market share, detailed hollow-fiber bioreactors market segments, market trends and opportunities, and any further data you may need to thrive in the hollow-fiber bioreactors industry. This hollow-fiber bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hollow-fiber bioreactors market consists of sales of membrane-based hollow-fiber bioreactors, perfusion hollow-fiber bioreactors, high-density hollow-fiber bioreactors, oxygen-permeable hollow-fiber bioreactors, and modular hollow-fiber bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.